Back To: Home : Featured Technology : Assay Development

CLICK HERE FOR WHAT'S NEW IN:
 

PerkinElmer’s Q4 profits rise 26% but CEO sees challenges
February 2008
SHARING OPTIONS:

WALTHAM, Mass.—PerkinElmer recently reported that its fourth-quarter revenues rose 20 percent and profits climbed 26 percent, with strong growth reported for both its Life and Analytical Sciences and Optoelectronics segments. Sales for its Life and Analytical Sciences segment rose 19 percent and Optoelectronics sales were up 22 percent.
"We continue to experience very good market conditions, across virtually every segment of the business, including newborn screening, prenatal and maternal health, molecular diagnostics, and now, cord blood," says Robert Friel, president and CEO. He also had this word of caution: "In drug discovery, we believe the market will continue to be challenging this year with large pharma again being under more cost pressures than the biotech firms or the academic lab."
Despite this, the company sees several areas of growth due to investments made previously in new products and acquisitions including cell-based assays, assay development services, custom synthesis of radiolabeled compounds, and cell imaging for high-content screening. "We're clearly seeing more growth on the reagent side than the instrument side," he notes. "So, our approach is to continue to drive new products particularly into the reagent area … particularly our cell-based assays and GPCR screening."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.